Impact of the time to achieve viral control on the dynamics of circulating HIV-1 reservoir in vertically infected children with long-term sustained virological suppression: A longitudinal study

Matías Moragas¹, Maximiliano Distefano¹, Debora Mecikovsky², Solange Arazi Caillaud², Carolina Cernadas³, Rosa Bologna², Paula Aulicino¹, Andrea Mangano¹*¹

¹ Laboratorio de Biología Celular y Retrovirus-CONICET, Hospital de Pediatria “Prof. Dr. Juan P. Garrahan”, Ciudad Autónoma de Buenos Aires, Argentina, ² Servicio de Epidemiología e Infectología, Hospital de Pediatria “Prof. Dr. Juan P. Garrahan”, Ciudad Autónoma de Buenos Aires, Argentina, ³ Dirección Asociada de Docencia e Investigación, Hospital de Pediatria “Prof. Dr. Juan P. Garrahan”, Ciudad Autónoma de Buenos Aires, Argentina

* amangan o@garr ahan.gov.ar, andreammangano@gmail.com

Abstract

Objective

Determine the decay rate of HIV-1 DNA reservoir in vertically infected children during sustained viral suppression (VS) and how it is affected by the age at VS.

Methods

This study included 37 HIV-1 vertically infected children on suppressive antiretroviral therapy for at least 4 years. Children were grouped according to the age of antiretroviral therapy initiation (< 0.5 or > 0.5 yrs) and to the age at VS (< 1.5, between > 1.5 and 4, and > > 4 years). Decay of cell-associated HIV-1 DNA (CA-HIV-DNA) level and 2-long terminal repeats (2-LTR) circles frequency were analyzed over 4 years of viral suppression using piecewise linear mixed-effects model with two splines and logistic regression, respectively.

Results

CA-HIV-DNA in peripheral blood mononuclear cells had a significant decay during the first two years of VS [-0.26 (95% CI: -0.43, -0.09) log₁₀ copies per one million cells (cpm)/year], and subsequently reached a plateau [-0.06 (95% CI: -0.15, 0.55) log₁₀ cpm/year]. The initial decay was higher in children who achieved VS by 1.5 years of age compared to those who achieved VS between > 1.5 and 4 years and those after 4 years of age: -0.51 (95% CI: -0.94, -0.07), -0.35 (95% CI: -0.83, 0.14), and -0.21 (95% CI: -0.39, -0.02) log₁₀ cpm PBMC/year, respectively. The 2-LTR circles frequency decayed significantly, from 82.9% at pre-VS to 37.5% and 28.1% at 2 and 4 years of VS, respectively (P = .0009).
Conclusions

These data highlight that achieving VS during the first 18 months of life limit the establishment of HIV-1 reservoirs, reinforcing the clinical benefit of very early effective therapy in children.

Introduction

Although antiretroviral therapy (ART) allows sustained viral suppression (VS) in blood plasma, the ability to eradicate human immunodeficiency virus type 1 (HIV-1) has not been yet achieved. The principal obstacle to viral eradication is the quick establishment of HIV-1 in its target cells, mainly in resting memory CD4+ T cells, at the earliest phases of primary infection [1–3]. The half-life of these resting cells can reach up to several years and contribute to the persistence of the infection, being recognized as the principal HIV-1 reservoir [4–6].

More than 150,000 new pediatric HIV-1 infections occurred globally during 2015. Mother-to-child transmission is still the main route of infection in children, despite the extended prophylaxis regimen: during pregnancy, intrapartum, and the first six weeks after birth [7]. Initially, ART was recommended only for children with acquired immunodeficiency syndrome-related symptoms (clinical stage C) or severe immune suppression (stage 3) [8]. However, in recent years, many studies reported that early initiation of ART in all HIV-1-infected children has clinical benefits [9,10]. Current HIV-1 treatment guidelines strongly recommend ART initiation as soon as possible after positive HIV-1 diagnosis, regardless of clinical and immunological conditions [11,12]. This counterpart to this scenario is that most HIV-1 infected infants do not have the opportunity to start ART soon after birth, drugs are inaccessible for many patients, and there are side effects associated with prolonged ART use [13]. Simplified ART regimens, including break periods or interruption schedules, are being studied in order to improve treatment adherence and reduce the toxic effects associated with the drugs [14,15]. These new therapeutic approaches that include HIV-1 infected patients with low to undetectable plasma viral load (pVL) require ongoing monitoring of the HIV-1 reservoir size. Estimation of the reservoir size could be important to determine patient response and avoid the possibility of pVL rebound. An effective biomarker to measure reservoir size and residual ongoing viral replication has not been established; however, cell-associated HIV-1 DNA (CA-HIV-DNA) and 2-long terminal repeat (2-LTR) circles levels, respectively, are commonly used for these purposes [16]. CA-HIV-DNA may remain detectable despite sustained undetectable pVL; thus, its level of decay might be of interest when assessing the long-term efficacy of ART on reservoirs. However, it is not well defined how the time to achieve sustained VS, particularly in those infants who controlled virus replication at chronic stage of infection, impacts on the size of the HIV-1 reservoir.

The present study was conducted to further understand how the time to achieve effective ART response affects the persistence of HIV-1 in children throughout successfully suppressed viremia. The specific aims were to determine the decay of viral reservoirs, estimated by CA-HIV-DNA and 2-LTR circles, during long-term VS in children initiating ART during acute and chronic stages of HIV-1 infection, and to assess the impact of the timing to achieve viral suppression on subsequent CA-HIV-DNA and 2-LTR circles decay.

Materials and methods

Study cohort

The initial cohort included 1,052 HIV-1 infected children who were treated at Hospital de Pediatría "Prof. Dr. Juan P. Garrahan", a referral pediatric hospital in Buenos Aires, Argentina.
From this cohort, a subset of 37 patients born between 1990 and 2008 were selected for analysis based on the following inclusion criteria: I) HIV-1 acquired by vertical transmission; II) VS present for \(\geq 4\) years; III) first ART regimen based on effective triple therapy, including two nucleoside reverse transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI); and IV) at least 2 available peripheral blood mononuclear cell (PBMC) or DNA samples for reservoir size quantification before ART initiation (pre-VS), and during 4 years of VS (Fig 1). Achieving two consecutive pVL below the limit of quantification (LoQ) of the available assay (range: 37–400 copies/mL) was defined as the beginning of sustained VS, and also maintaining this level along the study was defined as the maintenance of VS. Intermittent “blips” in the pVL after achieving VS were allowed, with blips defined as detectable pVL lower than 1000 copies of HIV-1 RNA/mL in one sample followed by undetectable levels. Patients were stratified according to the age at ART initiation \((\leq 0.5\) or \(>0.5\) yrs) and age to achieve VS \((\leq 1.5\), between \(>1.5\) and 4, and \(>4\) years). The study was approved by the Institutional Review Board (IRB) and Ethics Committee (EC) of Garrahan Pediatric Hospital (Protocol number: 856/2015). Written informed consent was obtained from parents or legal guardians. The consent process was approved by the IRB and EC.

For each patient included in the study, immunological data (CD4\(^+\) cell, CD8\(^+\) T cell, PBMC and monocyte counts), treatment history, and HIV-1 pVL data were collected.

**CA–HIV-DNA quantification and 2-LTR circles detection**

Genomic DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) from PBMC following the manufacturer’s protocols. DNA samples were stored at \(-20^\circ\)C until
use. The quantification of HIV-1 reservoirs, estimated by CA-HIV-DNA, was performed by semi-nested, real-time polymerase chain reaction (PCR) as previously described [17], with modification for amplification of ltr-gag region. A combination of previously published [18] primers-probe sets with newly designed ones based on subtype B, F, and B/F recombinant strains from the Los Alamos National Laboratory database were used. The LoQ of the assay was 0.78 log_{10} copies per one million (cpm) cells. B-globin quantification by real-time PCR was used to determine the number of PBMC present in each reaction.

Considering that variations of CD4^{+} T cell counts during HIV-1 infection may induce profound differences in CA-HIV-DNA levels, PBMC and monocyte counts through hemogram and CD4^{+} T cells counts by fluorescence-activated cell sorting were used to express CA-HIV-DNA levels in different units, as previously reported by Avettand-Fenoël et al [19]: log_{10} cpm PBMC, log_{10} cpm CD4^{+} T cells, and log_{10} copies/mL whole blood.

The 2-LTR circle was amplified and detected by hemi-nested real-time PCR using SYBR Green and a primer set targeting a conserved region of LTR-U5 and LTR-U3. A combination of previously published [18] primers with newly designed ones were used.

**Statistical analysis**

The trajectories of CA-HIV-DNA in PBMC, in the proportion of CD4^{+} T cells, and in whole blood over 4 years of VS were estimated by a piecewise linear mixed-effects model with a random slope for each child. The model included one change of slope at 2 years of VS based on the minimization of the Akaike information criterion and the immune population changes over the child’s age. In addition, time at VS and the presence of blips, both expressed as categorical variables, were included within the model to analyze their impact on CA-HIV-DNA levels in PBMC over the study period. ART regimen (grouped into NNRTI or PI) at VS and the basal pVL were tested to estimate the CA-HIV-DNA trajectories; however, they did not improve the model fit and were therefore not included in the final models. The frequency of 2-LTR circles following VS was studied using a generalized linear model -a logistic regression for repeated-measures- with the inclusion of CA-HIV-DNA level as a continuous variable.

The Mann-Whitney test and Kruskal-Wallis test were used to compare CA-HIV-DNA levels between two and more than two groups, respectively. Spearman’s correlation coefficient was used to evaluate the associations between CA-HIV-DNA levels reported in PBMC and those reported in CD4^{+} T cells and whole blood.

Statistical analyses were performed with R, version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

**Patient characteristics**

Baseline characteristics are reported in Table 1. Among the 37 children studied, the median age at ART was 2.4 [interquartile range (IQR), 0.8–5.1] years. Seven children started ART before 6 months of infection (IQR, 0.3–0.5 yrs) and 30 children after that time (IQR, 1.8–6.9 yrs). The majority of the children experienced a late effective response to ART, with a median age to achieve VS of 5.3 (IQR, 3.8–10.8) years. Only 4 (10.8%) children reached VS before 1.5 years, 6 (16.2%) children between >1.5 and 4 years, and 27 (73%) children after 4 years of age. In addition, 18 (48.6%) children had one or two blips during VS.
Cell-associated HIV-1 DNA kinetics

The size of peripheral blood HIV-1 reservoirs was estimated by the level of CA-HIV-DNA. Among all the patients studied, the CA-HIV-DNA level was below the LoQ at pre-VS in only 5 children; this level persisted over the study period in 3 children, while remaining 2 children experienced a sustained increment in the CA-HIV-DNA level during VS. Throughout VS, 26 (70.3%) patients had quantifiable CA-HIV-DNA levels, and 11 (29.7%) patients had at least one CA-HIV-DNA measure below LoQ.

The rate of decay and predicted mean level of CA-HIV-DNA estimated in PBMC, CD4\(^+\) T cells, and whole blood during VS are detailed in Table 2 and illustrated in Fig 2. The level of CA-HIV-DNA decayed significantly during the first two years of VS in all compartments, but it was more pronounced in CD4\(^+\) T cells than in whole blood and in PBMC: -0.41 [95% confidence interval (CI), -0.64 to -0.17] log\(_{10}\) cpm CD4\(^+\)/year, -0.34 (95% CI, -0.57 to -0.10) log\(_{10}\) copies/mL whole blood/year, and -0.26 (95% CI, -0.43 to -0.09) log\(_{10}\) cpm PBMC/year, respectively. However, the decay rate of CA-HIV-DNA after 2 years of VS was reduced and was not statistically significant in all compartments.

### Table 1. Patient characteristics.

| Characteristic                                      | Value |
|----------------------------------------------------|-------|
| Subjects, No.                                       | 37    |
| Sex, No. (%), Female                                | 19 (51.4) |
| ACTG 076 prophylaxis regimen, No. (%)\(^a\)         |       |
| - None                                             | 24 (64.9) |
| - Partial                                          | 5 (13.5) |
| - Complete                                         | 5 (13.5) |
| - Unknown                                          | 3 (8.1) |
| Age at ART initiation, median (IQR), yrs           | 2.4 (0.8–5.1) |
| First ART regimen, No. (%)                          |       |
| - 2 NRTIs + NNRTI                                   | 16 (43.2) |
| - 2 NRTIs + PI                                     | 21 (56.8) |
| Age at VS, median (IQR), yrs                       | 5.3 (3.8–10.8) |
| ART regimen at VS, No. (%)                         |       |
| - 2 NRTIs + NNRTI                                   | 23 (62.2) |
| - 2 NRTIs + PI                                     | 14 (37.8) |
| Time from ART initiation to VS, median (IQR), yrs  | 2.1 (0.5–4.1) |
| pVL at pre-VS, median (IQR), log\(_{10}\) copies/mL | 5.89 (5.03–6.25) |
| Immunologic population at pre-VS                   |       |
| - CD4\(^+\) T cell counts, median (IQR), %         | 19 (13–27) |
| - CD4\(^+\) T cell counts, median (IQR), cells/mm\(^3\) | 788 (325–1494) |
| - CD4:CD8 ratio, median (IQR)                       | 0.49 (0.39–0.67) |
| Immunologic population at end point                |       |
| - CD4\(^+\) T cell count, median (IQR), %          | 34 (30–39) |
| - CD4\(^+\) T cell count, median (IQR), cells/mm\(^3\) | 956 (691–1130) |
| - CD4:CD8 ratio, median (IQR)                       | 1.00 (0.78–1.29) |

\(^a\) Classification criteria based on ACTG 076: Complete, zidovudine administration to HIV-1 infected women during pregnancy and to the child during the first six weeks of life; Partial, zidovudine administration only to the HIV-1-infected pregnant woman or to the child; None, no zidovudine administration.

Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; pVL, plasma viral load; VS, viral suppression.

https://doi.org/10.1371/journal.pone.0205579.t001

### Cell-associated HIV-1 DNA kinetics

The size of peripheral blood HIV-1 reservoirs was estimated by the level of CA-HIV-DNA. Among all the patients studied, the CA-HIV-DNA level was below the LoQ at pre-VS in only 5 children; this level persisted over the study period in 3 children, while remaining 2 children experienced a sustained increment in the CA-HIV-DNA level during VS. Throughout VS, 26 (70.3%) patients had quantifiable CA-HIV-DNA levels, and 11 (29.7%) patients had at least one CA-HIV-DNA measure below LoQ. The rate of decay and predicted mean level of CA-HIV-DNA estimated in PBMC, CD4\(^+\) T cells, and whole blood during VS are detailed in Table 2 and illustrated in Fig 2. The level of CA-HIV-DNA decayed significantly during the first two years of VS in all compartments, but it was more pronounced in CD4\(^+\) T cells than in whole blood and in PBMC: -0.41 [95% confidence interval (CI), -0.64 to -0.17] log\(_{10}\) cpm CD4\(^+\)/year, -0.34 (95% CI, -0.57 to -0.10) log\(_{10}\) copies/mL whole blood/year, and -0.26 (95% CI, -0.43 to -0.09) log\(_{10}\) cpm PBMC/year, respectively. However, the decay rate of CA-HIV-DNA after 2 years of VS was reduced and was not statistically significant in all compartments.
compartments: -0.08 (95% CI, -0.14 to 0.80) log$_{10}$ cpm CD4$^+$ T-cells/year, -0.08 (95% CI, -0.79 to 0.63) log$_{10}$ copies/mL whole blood/year, and -0.06 (95% CI, -0.15 to 0.55) log$_{10}$ cpm PBMC/year.

The predicted mean level of CA-HIV-DNA in PBMC was 2.55 [95% prediction interval (PI), 2.18 to 2.93] log$_{10}$ cpm PBMC at VS and decayed to 2.03 (95% PI, 1.79 to 2.27) and 1.98 (95% PI, 1.66 to 2.30) log$_{10}$ cpm PBMC at 2 and 4 years of VS, respectively. These levels were lower than those expressed in the proportion of CD4$^+$ T cells and whole blood. However, CA-HIV-DNA levels in PBMC were highly correlated with those levels in CD4$^+$ T cells ($r = 0.97$, $P < .0001$) and in whole blood ($r = 0.98$, $P < .0001$).

Moreover, we observed a similar rate of decay in CA-HIV-DNA in PBMC between 2 and 4 years of VS in children who experienced the emergence of blips in comparison with those without blips: -0.02 (95% CI, -0.57 to 0.53) and -0.10 (95% CI, -0.63 to -0.44) log$_{10}$ cpm PBMC/year, respectively ($P = .5702$).

We further examined the effect of the age of infection at ART initiation on the level of CA-HIV-DNA in PBMC at 2 and 4 years of VS. The median level of CA-HIV-DNA in infants who started ART before 6 months of infection was 1.96 (IQR, 1.66–2.17) and 1.90 (IQR, 1.15–2.23) log$_{10}$ cpm PBMC at 2 and 4 years of VS, respectively, while infants who initiated ART afterward had a median level of 1.96 (IQR, 1.30–2.78) and 1.91 (IQR, 0.90–2.48) log$_{10}$ cpm PBMC at 2 and 4 years of VS, respectively. No significant difference was observed in the level of CA-HIV-DNA according to the time at ART initiation at 2 and 4 years of VS ($P = .7632$ and $P = .5701$, respectively).

Finally, we analyzed the decay rates of CA-HIV-DNA according to the age of infection at VS ($\leq 1.5$, >1.5–4, and >4 years). These results are shown in Table 3 and Fig 3. Slopes from children who achieved VS by 1.5 years of age and from those who achieved VS after 4 years of

Table 2. Estimated decay rates and predicted means of cell-associated HIV-1 DNA level over 4 years of sustained viral suppression and expressed in different units.

| Variable | PBMCs | CD4$^+$ cells | Whole Blood |
|----------|-------|---------------|-------------|
| No. of measurements | 98 | 92 | 93 |
| Intercept$^a$ | 2.44 (2.17 to 2.70) | 3.15 (2.79 to 3.50) | 3.01 (2.66 to 3.35) |
| First slope (0–2 yrs)$^b$ | -0.26 (-0.43 to -0.09) | -0.41 (-0.64 to -0.17) | -0.34 (-0.57 to -0.10) |
| - P-value$^c$ | .0028 | .0009 | .0056 |
| Second slope (2–4 yrs)$^b$ | -0.06 (-0.15 to 0.55) | -0.08 (-0.14 to 0.80) | -0.08 (-0.79 to 0.63) |
| - P-value$^c$ | .2578 | .1619 | .2842 |
| Level of CA-HIV-DNA$^d$ | 2.55 (2.18 to 2.93) | 3.35 (2.82 to 3.88) | 3.16 (2.64 to 3.68) |
| - At 0 yrs of VS, mean (95% PI) | 2.03 (1.79 to 2.27) | 2.53 (2.23 to 2.84) | 2.49 (2.20 to 2.78) |
| - At 2 yrs of VS, mean (95% PI) | 1.98 (1.66 to 2.30) | 2.38 (1.96 to 2.81) | 2.38 (1.97 to 2.80) |

$^a$The intercept represents the estimated basal level of CA-HIV-DNA and is expressed in different units by column: log$_{10}$ cpm PBMC, log$_{10}$ cpm CD4$^+$ T-cells, and log$_{10}$ copies/mL whole blood.

$^b$Slopes represent the decay rate of CA-HIV-DNA at different ages of VS and are expressed in different units by column: log$_{10}$ cpm PBMC/year, log$_{10}$ cpm CD4$^+$ T-cells/year, and log$_{10}$ copies/mL whole blood/year.

$^c$P-value represents the statistical significance of each decay rate in each compartment estimated by piecewise linear mixed-effects model.

$^d$Levels are expressed in different units by column: log$_{10}$ cpm PBMC, log$_{10}$ cpm CD4$^+$ T-cells, and log$_{10}$ copies/mL whole blood. The 95% PIs were predicted from the final model.

Abbreviations: CA-HIV-DNA, cell-associated HIV-1 DNA; CI, confidence interval; PBMC, peripheral blood mononuclear cell; PI, prediction interval; VS, viral suppression.

https://doi.org/10.1371/journal.pone.0205579.t002
age were significantly negative (P = .0235, P = .0287, respectively) during the first 2 years of VS. At that time, a higher decay rate of CA-HIV-DNA was observed in children who achieved VS by 1.5 years of age in comparison to those who achieved VS between 1.5 and 4 years and after 4 years of age: -0.51 (95% CI, -0.94 to -0.07), -0.35 (95% CI, -0.83 to 0.14), and -0.21 (95% CI, -0.39 to -0.02) log_{10} cpm PBMC/year, respectively. However, the overall difference among these slopes was not statistically significant (P = .1645). After 2 years of VS, CA-HIV-DNA decay rate (second slope) was very slow and similar among all groups, with no statistically significant value in any group (P = .7346). Furthermore, the predicted mean level of CA-HIV-DNA after 4 years of VS tended to be lower in children who achieved VS before 1.5 years of age compared to those with VS between 1.5 and 4 years and those after 4 years of age: 1.56 (95% PI, 0.75 to 2.37), 1.83 (95% PI, 0.94 to 2.73), and 2.08 (95% PI, 1.73 to 2.43) log_{10} copies/mL whole blood, respectively (P = .1942).

**Detection of 2-LTR circles and its association with CA-HIV-DNA levels**

Among the 37 patients included in the study, the presence of 2-LTR circles was determined in 35 patients at pre-VS, in 24 patients at 2 years of VS, and in 32 patients at 4 years of VS. The frequency of children with detectable 2-LTR circles decayed over VS, from 82.9% (29/35) at pre-VS to 37.5% (9/24) and 28.1% (9/32) at 2 and 4 years of VS, respectively. The logistic regression analysis for repeated measures showed a significant decay in the frequency of
2-LTR circles detection during VS (P = .0009). No significant difference in 2-LTR circles detection at 4 years of VS was observed among the children grouped according to the age at VS (1/3 patients 1.5 years or earlier, 1/4 between >1.5 and 4 years and 7/25 after 4 years of age). Furthermore, children with detectable 2-LTR circles showed a higher median level of CA-HIV-DNA compared to those with undetectable 2-LTR circles [2.48 (IQR, 1.68–3.01) vs. 1.89 (IQR, 0.78–2.39) log_{10} cpm, P < .005].

**Discussion**

In this study, we evaluated the evolution of HIV-1 reservoir size on PBMC in vertically HIV-1-infected children. Our results showed a marked decay of HIV-1 DNA reservoir size during the first two years of VS, being higher in those children with earlier age at VS. Then, this decay reaches a plateau independently of the age at viral suppression.

Reduced size of HIV-1 reservoirs has been reported in adults and children who started ART at early stage of infection. However, there are controversial results regarding what time is early enough to limit reservoir size and also it depends on which cell subset is studied [20–23]. The kinetics of HIV-1 reservoirs has been well reported in adults, but there are few studies in children, mainly analyzing the immediate effect after ART initiation and with short follow-up [24]. Notwithstanding, the kinetics of HIV-1 reservoirs in pediatric population over a long term of VS and how they are affected by the age at VS are poorly defined. In this study, we address these issues by studying longitudinally children who achieved effective response to ART at different times. It is important to mention, that due to the retrospectively design of the study and the availability of store PBMCs samples, most of the children started ART later and some who started early had a delay to achieve viral suppression. Nowadays, following international guidelines HIV infected children start ART soon after diagnosis (mainly during the first

### Table 3. Estimated decay rates and predicted means of cell-associated HIV-1 DNA level in PBMC over 4 years of sustained viral suppression according to the age at viral control.

| Variable                  | Age at VS | P-value<sup>d</sup> |
|---------------------------|-----------|---------------------|
|                           | ≤1.5 yrs  | >1.5–4 yrs | >4 yrs |
| No. of children           | 4         | 6         | 27     | NA    |
| Intercept<sup>a</sup>     |           |           |        |       |
| - Estimated (95% CI)      |           |           |        |       |
| First slope (0–2 yrs)<sup>b</sup> |           |           |        |       |
| - Estimated (95% CI)      |           |           |        |       |
| - P-value<sup>c</sup>     |           |           |        |       |
| Second slope (2–4 yrs)<sup>b</sup> |           |           |        |       |
| - Estimated (95% CI)      |           |           |        |       |
| - P-value<sup>c</sup>     |           |           |        |       |
| Level of CA-HIV-DNA (log<sub>10</sub> cpm PBMC) |           |           |        |       |
| - At 0 yrs of VS, mean (95% PI) |           |           |        |       |
| - At 2 yrs of VS, mean (95% PI) |           |           |        |       |
| - At 4 yrs of VS, mean (95% PI) |           |           |        |       |

<sup>a</sup>The intercept represents the estimated basal level of CA-HIV-DNA and is expressed in log_{10} cpm PBMC.

<sup>b</sup>Slopes represent the decay rate of CA-HIV-DNA at different ages of VS for each group and they are expressed in log_{10} cpm PBMC/year.

<sup>c</sup>P-value represents the statistical significance of each decay rate in each group estimated by piecewise linear mixed-effects model.

<sup>d</sup>P-value represents the statistical significance of the comparison among children with age at VS of ≤1.5, >1.5–4, and >4 years.

Abbreviations: CA-HIV-DNA, cell-associated HIV-1 DNA; CI, confidence interval; PBMC, peripheral blood mononuclear cell; PI, prediction interval; NA, not applicable; VS, viral suppression.

https://doi.org/10.1371/journal.pone.0205579.t003
year of life). However, in resource-limiting countries a delay in pediatric HIV diagnosis is still frequent with the consequently late initiation of therapy. Hence, exploring the dynamics of the viral reservoirs in these populations might bring insights of their behavior in well-established infection in children. Moreover, these patients might serve as good control groups for studies comparing the kinetics of viral reservoirs in children who start ART at early or very early steps of infection.

Our results showed a significant decay rate of CA-HIV-DNA level over the first two years of sustained VS. This was in concordance with previous studies performed in adults by Laanan et al [20] and Besson et al [25]. However, after 2 years of VS, the level of CA-HIV-DNA remained almost in a steady state. This plateau phase of CA-HIV-DNA might reflect ongoing viral replication or viral release from stable reservoirs [26–28]. Additionally, survival of long-lived HIV-1 infected cells could be another key factor contributing to the stability of the reservoir size, but their persistence during 4 years of VS is unlikely.

Activation of target cells and latently infected cells by concurrent infection or immune suppression by opportunistic infections might contribute to ongoing viral replication [29]. In our cohort, children with and without blips (48.6% vs 51.4%) had no difference in the decay rate of CA-HIV-DNA over VS, suggesting that a transitory viral rebound seems not to be enough to modify the whole size of HIV-1 reservoirs. In contrast, Ramratnam et al [30] observed that the rate of decay of HIV-1 reservoir is inversely correlated with the extent of residual viral replication during ART. Whether the time elapsed to recover VS since viral rebound occurred or if the highest level of viremia at rebound could modify reservoir size need to be addressed.

Fig 3. Decay rates of CA-HIV-DNA from children with sustained viral suppression according to the age of infection at VS. Individual lines indicate the trajectories of CA-HIV-DNA based on the model prediction. Individual points represent the quantification of HIV-1 DNA from each patient at specific time points.

https://doi.org/10.1371/journal.pone.0205579.g003
It is accepted that the earlier ART is initiated, the smaller the size of the HIV-1 reservoir [24]. However, we did not observe differences in the CA-HIV-DNA level after 4 years of VS between children starting ART before (n = 7) and after (n = 30) six months of age. This could be explained in part by the unbalanced number of children in both groups and also by a late effective viral control observed in our cohort despite early ART initiation. Furthermore, a recent study showed an absence of significant difference in CA-HIV-DNA levels during 96 weeks of ART among children who started ART before and after 6 weeks of life [31]. These findings suggest that the establishment of HIV-1 reservoirs occur very early—probably during the first hours after infection, that could be in utero as the Mississippi child [32].

We further analyzed whether there was an association between the age at VS and the decay rate of CA-HIV-DNA during VS. We found that the decay rate of CA-HIV-DNA during the first two years of VS tended to be higher in children who reached effective viral control by 1.5 years of age than in those beyond 1.5 years. Additionally, the predicted level of CA-HIV-DNA at 4 years of VS was lower when the time at VS was ≤1.5 years of age. In line with our findings, Persaud and colleagues reported, in a cross-sectional study, a significant difference in CA-HIV-DNA levels after 7.2 years of VS among children who suppressed plasma viremia before 1 year and after 5 years of age [33]. However, the authors did not find a significant difference between the groups who achieved VS before 1 year compared to 1–5 years or between the latter group and those after 5 years of age.

There are many controversies regarding data concerning the stability of 2-LTR circles and, in consequence, its value as a surrogate marker for ongoing replication. Some studies reported that 2-LTR circles are labile forms and thus their presence is indicative of recent infection events [34,35]. However, other studies indicated that these episomal HIV-1 forms are intrinsically stable in vitro [36,37]. In the present study, we found that, at ART initiation, even with high pVL (approximately 5 log_{10} copies/mL), 80% of the children had detectable levels of 2-LTR circles. This could reflect a methodological limitation since we isolated total DNA from PBMC instead of episomal DNA, which seems to improve 2-LTR circles detection [38]. Similar to the frequency observed with CA-HIV-DNA, the frequency of children with detectable 2-LTR circles significantly decreased over VS, and it was higher (28%) than it was reported by Koelsch et al [39] even at 4 years of VS. This level could be even higher taking into account the methodological limitation discussed above. Two main hypotheses might explain this: (1) ongoing viral replication during VS manifested by residual viremia allows de novo generation of HIV-1 episomal forms or (2) 2-LTR circles generated before suppressive ART persists for longer time than expected, remaining detectable even during many years of sustained VS in children.

Some limitations of the present study include the predominance of children with late effective response to ART, resulting in some groups analyzed being imbalanced; therefore, the decay of HIV-1 reservoirs in those groups might be underpowered. Also, the subjective data on ART adherence in our pediatric cohort could underestimate the impact of time at ART initiation on HIV-1 reservoirs. On the other hand, it is important to highlight that molecular DNA assays could overestimate the size of the reservoirs since they detect intact and defective viruses [16,40].

The high level and the low decay rate of CA-HIV-DNA during VS found in our study seem to be an obstacle for ART-free remission. However, it has been previously reported that more than 95% of CA-HIV-DNA is defective to produce replication-competent viruses [41,42]. In this sense, the adults ANRS VISCONTI cohort study [43] and, more recently, the French ANRS EPF-CO10 pediatric cohort [44] demonstrated that functional cure could be achieved without complete elimination of CA-HIV-DNA. In a recent, very novel study, Imamichi and colleagues [41] proposed that defective proviruses are capable of transcribing unspliced HIV-1
RNA producing intact HIV-related proteins in patients receiving ART who suppressed pVL for many years. Collectively, these findings lead to a new understanding of the role of CA-HIV-DNA in HIV-1 cure studies.

In conclusion, our data highlight the difficulty to eliminate the circulating reservoirs from peripheral blood. Also, our results support that the age to reach VS may be a better predictor of the size of HIV-1 reservoirs on PBMC in children after a prolonged time of VS than the age at ART initiation, reinforcing the clinical benefit of very early effective therapy.

Supporting information
SI Table. Cohort data set.
(XLSX)

Acknowledgments
We gratefully thank Dr. Luisa Sen for virtually reviewing the manuscript. We also thank Mrs. Silvina Juarez and Romina Guelho for their technical assistance.

Author Contributions
Conceptualization: Matías Moragas, Debora Mecikovsky, Solange Arazi Caillaud, Rosa Bologna, Paula Aulicino, Andrea Mangano.
Data curation: Matías Moragas, Maximiliano Distefano, Carolina Cernadas.
Formal analysis: Matías Moragas, Maximiliano Distefano, Debora Mecikovsky, Solange Arazi Caillaud, Rosa Bologna, Paula Aulicino.
Funding acquisition: Andrea Mangano.
Investigation: Matías Moragas, Andrea Mangano.
Methodology: Matías Moragas, Maximiliano Distefano.
Project administration: Andrea Mangano.
Resources: Andrea Mangano.
Software: Matías Moragas, Maximiliano Distefano.
Supervision: Andrea Mangano.
Writing – original draft: Matías Moragas, Andrea Mangano.
Writing – review & editing: Matías Moragas, Maximiliano Distefano, Debora Mecikovsky, Solange Arazi Caillaud, Rosa Bologna, Paula Aulicino, Andrea Mangano.

References
1. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995; 1: 1284–90. PMID: 7489410
2. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997; 387: 183–8. https://doi.org/10.1038/387183a0 PMID: 9144289
3. Persaud D, Pierson T, Ruff C, Finzi D, Chadwick KR, Margolick JB, et al. A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children. J Clin Invest. 2000; 105: 995–1003. https://doi.org/10.1172/JCI9006 PMID: 10749578
4. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999; 5: 512–7. https://doi.org/10.1038/9394 PMID: 10229227

5. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003; 9: 727–728. https://doi.org/10.1038/nm880 PMID: 12754504

6. Eisele E, Siliciano RF. Redefining the Viral Reservoirs that Prevent HIV-1 Eradication. Immunity. Elsevier Inc.; 2012; 37: 377–388. https://doi.org/10.1016/j.immu.2012.08.010 PMID: 2299944

7. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact sheet 2016. GLOBAL STATISTICS —2015. 2016. Available from: http://www.unaids.org/.

8. World Health Organization. Antiretroviral therapy of HIV infection in children and towards universal access. Recommendations for a public health approach HIV/AIDS Programme. 2007. Available from: http://www.who.int/.

9. Violiari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359: 2233–44. https://doi.org/10.1056/NEJMoa0800974 PMID: 19020325

10. Chiappini E, Galli L, Tovo P-A, Gabiano C, Lisi C, Bernardi S, et al. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis. 2009; 9: 140. https://doi.org/10.1186/1471-2334-9-140 PMID: 19709432

11. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015. Available from: http://apps.who.int/.

12. U.S. Department of Health and Human Services. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2016. Available from: http://aidsinfo.nih.gov.

13. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther. 2007; 12: 1247–54.

14. Wamalwa D, Benkni-Nugent S, Langat A, Tapia K, Moraa H, et al. Treatment interruption after 2-year antiretroviral treatment (ART) initiated during acute/early HIV in infancy: a randomized trial. AIDS. 2016; 30(15):2303–13. https://doi.org/10.1097/QAD.0000000000001158 PMID: 27177316

15. Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised. Lancet Infect Dis. 2014; 14: 572–580. https://doi.org/10.1016/S1473-3099(14)70736-4 PMID: 24783988

16. Eriksson S, Graf EH, Dahl V, Strain MC, Yuki SA, Lysenko ES, et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathog. 2013; 9(2):e1003174.

17. Pasternak AO, Adema KW, Bakker M, Jurriaans S, Berkhout B, Cornelissen M, et al. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol. 2008; 46: 2206–2211. https://doi.org/10.1128/JCM.00055-08 PMID: 18463204

18. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med. 2001; 7: 631–634. https://doi.org/10.1038/87979 PMID: 11329067

19. Avettand-Fenoël V, Boufassa F, Galimand J, Meyer L, Rouzioux C. HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol. 2008; 42: 399–404. https://doi.org/10.1016/j.jcv.2008.03.013 PMID: 18455956

20. Laanani M, Ghosn J, Essat A, Melard A, Seng R, Gousset M, et al. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clin Infect Dis. 2015; 60: 1715–1721. https://doi.org/10.1093/cid/civ171 PMID: 25733734

21. Bitun A, Samson L, Chun TW, Kakkar F, Brophy J, Murray D, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. Clin Infect Dis. 2014; 59: 1012–1019. https://doi.org/10.1093/cid/ciu432 PMID: 24917662

22. Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, et al. Dynamics of the resting CD4(+)+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS. 2012; 26: 1483–90. https://doi.org/10.1097/QAD.0b013e328353638 PMID: 2255165

23. Martinez-Bonet M, Puertas MC, Fortuny C, Ouchi D, Mellado MJ, Rojo P, et al. Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early
Pediatric HIV DNA dynamics over viral suppression

24. Avettand-Fenoël V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, et al. Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. Clin Microbiol Rev. 2016; 29: 859–80. https://doi.org/10.1128/CMR.00015-16 PMID: 27559075

25. Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014; 59: 1312–21. https://doi.org/10.1093/cid/civ456 PMID: 25073894

26. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010; 16: 460–5. https://doi.org/10.1038/nm.2111 PMID: 20228817

27. Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012; 59: 29–35.

28. Noel N, Peña R, David A, Avettand-Fenoel V, Erkizia I, Jimenez E, et al. Long-Term Spontaneous Control of HIV-1 is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. J Virol. 2016; 90: 6148–58. https://doi.org/10.1128/JVI.00149-16 PMID: 27122576

29. Laura E. Jones ASP. Transient Viremia, Plasma Viral Load, and Reservoir Replenishment in HIV-Infected Patients on Antiretroviral Therapy. J Acquir Immune Defic Syndr. NIH Public Access; 2007; 45 (5): 483.

30. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000; 6: 82–5. https://doi.org/10.1038/nm71577 PMID: 10613829

31. Uprety P, Chadwick EG, Rainwater-Lovett K, Ziemniak C, Luzuriaga K, Capparelli E V., et al. Cell-Associated HIV-1 DNA and RNA Decay Dynamics during Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. Clin Infect Dis. 2015; 61: 1862–1870. https://doi.org/10.1093/cid/civ688 PMID: 26270687

32. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun T-W, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013; 369: 1828–35. https://doi.org/10.1056/NEJMoa1302976 PMID: 24152233

33. Persaud D, Patel K, Karalius B, Rainwater- K, Ziemniak C, Ellis A, et al. Age at Virologic Control Influences Peripheral Blood HIV Reservoir Size and Serostatus in Perinatally-Infected Adolescents. JAMA Pediatr. 2015; 168: 1138–1146.

34. Panther LA, Coombs RW, Aung SA, dela Rosa C, Gretch D, Corey L. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. J Med Virol. 1999; 58: 165–73. PMID: 10335865

35. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 2000; 6: 78–81. https://doi.org/10.1038/71569 PMID: 10613828

36. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol. 2002; 76: 4138–44. https://doi.org/10.1128/JVI.76.8.4138-4144.2002 PMID: 11907256

37. Malatinkova E, Kiselinova M, Bonczkowski P, Trypsteen W, Messiaen P, Vermeire J, et al. Accurate quantification of episomal HIV-1 two-long terminal repeat circles by use of optimized DNA isolation and droplet digital PCR. J Clin Microbiol. 2015; 53: 699–701. https://doi.org/10.1128/JCM.03087-14 PMID: 25502524

38. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, et al. Dynamics of Total, Linear Nonintegrated, and Integrated HIV-1 DNA in Vivo and In Vitro. J Infect Dis; 2008; 197(3):411–9. https://doi.org/10.1086/525283 PMID: 18248304

39. Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L. Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathog. 2016; 12(3):e1005472. https://doi.org/10.1371/journal.ppat.1005472 PMID: 26938995

40. Imamichi H, Dewar RL, Adelsberger JW, Rehm CA, O’Doherty U, Paxinos EE, et al. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination
antiretroviral therapy. Proc Natl Acad Sci. National Academy of Sciences; 2016; 113(31):8783–8. https://doi.org/10.1073/pnas.1609057113 PMID: 27432972

42. Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferrí AA, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med. 2016; 22(9):1043–9. https://doi.org/10.1038/nm.4156 PMID: 27500724

43. Sáez-Cirión AA, Bacchus C, Hocqueloux L, Avettand-Fenoël V, Girault I, Lecouroux C, et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoSPathog. 2013; 9(3):e1003211.

44. Frange P, Faye A, Avettand-Fenoël V, Bellaton E, Descamps D, Angin M, et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV. Elsevier; 2016; 3: e49–e54. https://doi.org/10.1016/S2352-3018(15)00232-5 PMID: 26762993